Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218208 | 0.84 | KDM4E (0.61) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL14298815 | 0.82 | MEN1 (0.45) | KDM4ENPC1RAB9ACYP1A2CYP2C9 | |
| SCHEMBL4094356 | 0.80 | KDM4E (0.71) | KDM4EUSP2KDRNPC1RAB9A | |
| SCHEMBL29733664 | 0.80 | KDM4E (0.71) | KDM4EUSP2KDRNPC1RAB9A | |
| SCHEMBL8221922 | 0.80 | GABRA1 (0.46) | KDRNPC1RAB9AHPGDMEN1 | |
| SCHEMBL25268941 | 0.78 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL3270763 | 0.78 | BRAF (0.50) | KDM4EUSP2BRAFMAPK14MAPK13 | |
| SCHEMBL8207607 | 0.78 | PDE10A (0.54) | KDM4EUSP2NPC1RAB9ACYP1A2 | |
| SCHEMBL8205594 | 0.77 | GABRA1 (0.47) | KDM4ENPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3272695 | 0.76 | KDM4E (0.49) | KDM4EUSP2SRCBRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825254-B2 | Heteroaromatic quinoline compounds | PFIZER INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | disclosed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PDE12, PDE7A, PDE4A | KDM4E 1059/4885USP2 1864/4885SRC 4244/4885 |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PDE12, PDE7A, PDE4A | KDM4E 1059/4885USP2 1864/4885SRC 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.